Are we really still pretending that bigger pharmaceutical companies automatically have better pharmacovigilance systems? The assumption feels ingrained in Silicon Valley – that scale equals sophistication – but the reality, as Vikalp Khare, head of U.S. GPV safety data management at Otsuka, points out, is far more nuanced. The real story here isn't the size of the pharma giant; it’s the rigor of the risk-based evaluation applied to every trial, regardless of who’s sponsoring it. We’ve become so fixated on the promise of AI and automation in drug safety that we’ve forgotten the foundational principle: a robust system isn’t about the bells and whistles, it’s about responsibility. And that responsibility begins with ensuring the right technology, configuration, and governance for the specific program at hand.
For years, the narrative has been that large pharmaceutical organizations boast well-established pharmacovigilance ecosystems – validated databases, standardized configurations, integrated tools. And that’s often true. But maturity doesn’t guarantee alignment with evolving requirements. Each new study, particularly those involving novel therapies, decentralized data, or expanding global reach, introduces complexity that legacy systems often struggle to handle. It’s a bit like assuming your trusty family sedan can suddenly handle an off-road rally – it might get you somewhere, but it’s not designed for the terrain. Interestingly, Khare has observed smaller organizations, unburdened by historical constraints, architecting surprisingly streamlined and modern solutions. They can implement forward-looking, automation-driven models faster than larger enterprises wrestling with decades of accumulated technical debt.
This isn’t to say that smaller biotechs are inherently better equipped. It’s about a mindset. The assumption that an existing technology suite is “good enough” is dangerous, whether you’re a multinational corporation or a startup. The cost of complacency in pharmacovigilance isn’t measured in dollars; it’s measured in patient safety. Consider the recent surge in personalized medicine and gene therapies. These aren’t incremental improvements on existing drugs; they’re fundamentally different. Applying a standard safety database configuration to a novel gene therapy is like trying to fit a square peg into a round hole – you might force it, but you’re creating vulnerabilities. In 2023, the FDA issued a record number of warning letters related to data integrity, many stemming from inadequate system validation – a clear signal that even established players are struggling to keep pace.
Original reporting: clinicalleader.com.
The choice of PV technology – whether to stick with established vendors or explore newcomers – is a constant tension. There are, of course, the usual suspects in the PV tech space, offering maturity, regulatory credibility, and global support. But defaulting to the “trusted few” isn’t a strategy; it’s a risk avoidance tactic. Khare advocates for a structured, risk-based, future-focused view. Assessing true requirements – regulatory complexity, portfolio size, integration landscape, inspection readiness, and total cost of ownership – is paramount. It’s a bit like building a house: you don’t just choose the prettiest materials; you choose the ones that can withstand the climate and support the structure. He’s seen emerging solutions in AI-driven case processing and advanced analytics show promise, but innovation must be balanced with regulatory robustness. A flashy new tool is useless if it can’t stand up to scrutiny during a health authority inspection.
What’s often overlooked is the wealth of historical knowledge within a company. Technology selection shouldn’t be driven by market positioning or feature comparison, but by what has worked – and what has failed. Khare emphasizes leveraging upgrade experiences, global user feedback, integration history, vendor performance, and inspection history. This isn’t about dwelling on past mistakes; it’s about learning from them. It’s the difference between blindly repeating the same process and iteratively improving it. Think of it like a seasoned chef refining a recipe – they don’t discard the entire dish after a minor flaw; they adjust the ingredients and technique to achieve a better result. A company’s past is its most valuable strategic asset, if it chooses to learn from it.
But even with a solid understanding of past performance, certain trial-specific factors demand a reassessment of PV technology. Novel modalities, geographic expansion, complex trial designs, increased scrutiny, and portfolio life cycle stage all introduce new risks. A trial spanning multiple regions, for example, requires navigating different reporting formats, timelines, and data privacy regulations. Ignoring these nuances can lead to compliance violations and, ultimately, jeopardize patient safety. The FDA’s increasing focus on real-world evidence (RWE) adds another layer of complexity, requiring systems capable of integrating and analyzing data from diverse sources. This isn’t about over-engineering; it’s about proactively adapting to evolving scientific and regulatory landscapes.
The timing of this assessment is crucial. Khare argues that it should begin as soon as there’s clarity on the trial’s design and geographic footprint – well before the study is active. Starting early allows sufficient time for risk-based assessments, vendor evaluations, and validation planning. Waiting until the last minute forces teams to compromise, increasing both compliance risk and operational burden. It’s a simple principle: proactive planning is a safeguard. The non-negotiables, he stresses, are regulatory compliance, robust validation, integration capability, data governance, configuration flexibility, and scalability. These aren’t optional features; they’re fundamental requirements.
Ultimately, the choices we make in PV technology directly impact case quality, regulatory compliance, and long-term scalability. A well-configured system empowers case processors, strengthens compliance posture, and allows organizations to grow confidently. A poorly chosen system creates workarounds, increases risk, and hinders innovation. The industry needs to move beyond the hype surrounding AI and automation and focus on the foundational principles of patient safety and regulatory defensibility.
Looking ahead, I predict we’ll see a significant increase in demand for “composable” PV systems – platforms that allow organizations to selectively integrate best-of-breed technologies rather than relying on monolithic, all-in-one solutions. The question isn’t if this shift will happen, but when will the established vendors adapt, or will nimble newcomers disrupt the market by offering the flexibility and agility that today’s trials demand?
